Esketamine - Auris Medical/INSERM/University of Montpellier

Drug Profile

Esketamine - Auris Medical/INSERM/University of Montpellier

Alternative Names: (s)-ketamine; AM-101; Keyzilen

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Auris Medical; INSERM; University of Montpellier I
  • Developer Auris Medical
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Tinnitus

Most Recent Events

  • 09 May 2017 Efficacy and adverse events data from the phase III AMPACT1 trial in Tinnitus released by Auris Medical
  • 24 Apr 2017 Efficacy and adverse events data from the phase III AMPACT2 trial in Tinnitus released by Auris Medical
  • 01 Jan 2017 Auris Medical completes the AMPACT1 trial in Tinnitus in USA and Czech Republic (Intratympanic) (NCT01934010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top